Neurocrine Partners With Dainippon To Market Indiplon In Japan
This article was originally published in The Pink Sheet Daily
Deal includes payments based on approval of insomnia agent in both Japan and the U.S.
You may also be interested in...
Sleep aid could at last reach market late in 2008.
Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.